DiscGenics

Disc Genics

Biotechnology, 5940 W Harold Gatty Dr, Salt Lake City, Utah, 84116, United States, 11-50 Employees

discgenics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 80********

Who is DISCGENICS

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with ...

Read More

map
  • 5940 W Harold Gatty Dr, Salt Lake City, Utah, 84116, United States Headquarters: 5940 W Harold Gatty Dr, Salt Lake City, Utah, 84116, United States
  • 2007 Date Founded: 2007
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from DISCGENICS

DiscGenics Org Chart and Mapping

Employees

Bob Wynalek

Chief Operating Officer & Chief Commercialization Officer

Lisa Flood

Senior Director, Clinical, Regulatory

Samantha Coyne

Qc Analyst III and Validation

Hannah Loftus

Scientist, Lead Donor Procurement Coordinator

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding DiscGenics

Answer: DiscGenics's headquarters are located at 5940 W Harold Gatty Dr, Salt Lake City, Utah, 84116, United States

Answer: DiscGenics's phone number is 80********

Answer: DiscGenics's official website is https://discgenics.com

Answer: DiscGenics's revenue is $1 Million to $5 Million

Answer: DiscGenics's SIC: 8731

Answer: DiscGenics's NAICS: 541714

Answer: DiscGenics has 11-50 employees

Answer: DiscGenics is in Biotechnology

Answer: DiscGenics contact info: Phone number: 80******** Website: https://discgenics.com

Answer: DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access